# A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

> **NCT02905578** · PHASE2 · COMPLETED · sponsor: **Joseph J. Cullen** · enrollment: 40 (actual)

## Conditions studied

- Pancreatic Neoplasms
- Cancer of Pancreas
- Cancer of the Pancreas
- Neoplasms, Pancreatic
- Pancreas Cancer
- Pancreas Neoplasms
- Adenocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** nab-paclitaxel
- **DRUG:** Pharmacological ascorbate

## Key facts

- **NCT ID:** NCT02905578
- **Lead sponsor:** Joseph J. Cullen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-28
- **Primary completion:** 2024-08-26
- **Final completion:** 2024-08-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-08-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02905578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02905578, "A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02905578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*